Nephrotic Syndrome (Minimal Change Disease)
The kidney disease in the 1940s that caused prolonged hospitalization and required repeated high-dose corticosteroid injections was nephrotic syndrome, most commonly due to minimal change disease (MCD) in children. This condition became one of the first glomerular diseases to be treated with corticosteroids following their introduction in the early 1950s 1, 2.
Historical Context
Glucocorticoids were first introduced for clinical use around 1948-1950, initially for rheumatoid arthritis, and quickly expanded to renal diseases 2. By the early 1950s, corticosteroids had proven to be particularly beneficial in minimal change nephrotic syndrome, establishing it as one of the few glomerulonephritides where glucocorticoid therapy demonstrated clear efficacy 1.
Why This Disease Required Prolonged Hospitalization
Patients with nephrotic syndrome in the 1940s-1950s faced:
- Severe proteinuria leading to profound hypoalbuminemia (often <2.5 g/dL)
- Massive edema requiring intensive diuretic management and fluid monitoring
- High risk of life-threatening complications including:
- Thromboembolism (due to urinary loss of anticoagulant proteins)
- Severe infections (from immunoglobulin loss and immunosuppression)
- Acute kidney injury from intravascular volume depletion
The Steroid Treatment Protocol
The introduction of corticosteroid therapy revolutionized management but required:
- High-dose intravenous methylprednisolone pulses followed by oral prednisone 3
- Extended treatment courses of 6 months or longer to achieve and maintain remission 3
- Close monitoring for both disease response and steroid-related complications
- Repeated courses for patients with frequent relapses or steroid-dependent disease 4
Modern Context
Current KDIGO guidelines 5, 6 still recommend high-dose corticosteroids as first-line therapy for MCD, though with more refined protocols:
- Initial dose: Oral prednisone 1 mg/kg/day (maximum 80 mg/day) or 2 mg/kg every other day (maximum 120 mg/day)
- Duration: Continue until remission, then taper over 6 months total
- Monitoring: Most patients show improvement within 4-8 weeks 6
Common pitfall: The high toxicity of prolonged high-dose corticosteroids (growth retardation in children, metabolic syndrome, infections, osteoporosis) 1 necessitates early transition to steroid-sparing agents like calcineurin inhibitors or rituximab in steroid-dependent or frequently relapsing cases 5, 6.
The historical significance lies in MCD being one of the first kidney diseases where corticosteroid therapy dramatically improved outcomes, transforming a condition that previously required months of hospitalization into one that could be managed with outpatient therapy once the acute phase resolved.